BMI View: Moldova's pharmaceutical market presents very limited opportunities for multinational
drugmakers, in comparison to its neighbours in Eastern Europe. The country's small total market size and
its reliance on out-of-pocket payments highlight the challenges it poses. Moreover, continued economic
weakness and negative demographic trends will limit growth prospects.
Headline Expenditure Projections
? Pharmaceuticals: MDL5.83bn (USD310mn) in 2015 to MDL6.23bn (USD322mn) in 2016; 6.7% in
local currency terms and 3.8% in US dollar terms. Forecast unchanged from previous quarter.
? Healthcare: MDL12.32bn (USD654mn) in 2015 to MDL13.27bn (USD686mn) in 2015; +7.7% in local
currency terms and 4.8% in US dollar terms. Forecast unchanged from previous quarter.